GCM
IMRX icon

Ghisallo Capital Management’s Immuneering IMRX Stock Holding History

Ghisallo Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$398K – 484
2021
Q3 		$398K Buy
+15,000
New +$403K 0.02% 412

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghisallo Capital Management's IMRX Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Immuneering (IMRX) in Q4 2021, closing a stake of 15,000 shares — an estimated $398K sold.

Ghisallo Capital Management first reported a position in IMRX in Q3 2021 and held it in 1 quarter. The position peaked at $398K in Q3 2021. 37 funds tracked by Wall St. Rank hold IMRX as of Q4 2021.

  • Ghisallo Capital Management reported no remaining Immuneering position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 15,000 Immuneering shares in Q4 2021, an estimated $398K.
  • Ghisallo Capital Management first reported a position in Immuneering in Q3 2021 and held it in 1 quarter.
  • Ghisallo Capital Management's Immuneering position peaked at $398K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Immuneering as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.